What comprehensive testing reveals about the biological roots of depression—and why addressing them changes outcomes
Depression is now the leading cause of disability worldwide, and the numbers have only gotten worse since the pandemic. Yet our primary treatment strategy—prescribing antidepressants and hoping for the best—leaves the majority of people still struggling. If you’ve been told that depression is simply a “chemical imbalance” requiring medication, you’ve been given an incomplete picture. Functional medicine for depression offers a more complete one.
This isn’t about rejecting medication. It’s about asking a better question: What is driving this person’s depression in the first place?
The Problem with the Standard Approach
Let’s start with some uncomfortable data.
The STAR*D trial remains the largest real-world study of antidepressant treatment ever conducted. Over 4,000 patients with major depression were enrolled and treated through up to four sequential medication trials. The original investigators reported a cumulative remission rate of 67%—a number that shaped clinical practice for nearly two decades [1]. However, a rigorous 2023 reanalysis of the original patient-level data found that when analyzed according to the study’s own prespecified protocol, the actual cumulative remission rate was closer to 35% [2]. That means roughly two-thirds of patients did not achieve remission even after multiple aggressive medication trials.
The picture gets harder when you look at relapse. Among those who did achieve remission, relapse rates during the follow-up period ranged from 40% to 71%, with higher relapse rates among those who required more treatment steps to get there [1]. In other words, the more difficult depression was to treat initially, the more likely it was to return.
Meanwhile, a widely discussed 2022 umbrella review published in Molecular Psychiatry found no consistent evidence supporting the longstanding hypothesis that depression is caused by lowered serotonin activity [3]. This doesn’t mean SSRIs never help—they clearly do for some people—but it does mean we’ve been oversimplifying the biology of depression for decades. The “chemical imbalance” narrative told patients that their depression was a serotonin problem requiring a serotonin solution. The reality is far more complex.
It’s worth noting that the Moncrieff review generated significant debate. A group of 36 experts published a formal response arguing the review had methodological limitations and selectively interpreted findings [4]. What both sides agree on, however, is that depression cannot be reduced to a single neurotransmitter problem. And that’s exactly where functional medicine enters the conversation.
Depression as a Syndrome, Not a Single Disease
The Institute for Functional Medicine (IFM) teaches practitioners to approach depression the way an infectious disease specialist approaches pneumonia: as a syndrome with multiple possible underlying causes. You can have pneumococcal pneumonia, mycoplasma pneumonia, or viral pneumonia—same symptoms, very different treatment. Depression works the same way.
A person’s depression might be driven primarily by gut inflammation. Or by HPA axis dysregulation. Or by nutrient deficiencies that starve the brain of raw materials it needs to produce neurotransmitters. Or by thyroid dysfunction that falls within “normal” lab ranges but is suboptimal for brain function. Or by some combination of all of these. The IFM framework uses the Functional Medicine Matrix—organizing clinical imbalances across nodes of assimilation, defense and repair, energy, biotransformation, communication, transport, and structural integrity—to systematically identify which systems are contributing to a given patient’s depression.
This is what makes functional medicine for depression fundamentally different from conventional psychiatry: instead of matching a diagnosis to a drug, you’re investigating which biological systems are dysfunctional and addressing them directly.
The Biological Systems That Drive Depression
Inflammation: The Hidden Engine
Research over the past two decades has fundamentally changed how we understand the biology of depression. A landmark meta-analysis found that people with major depression have significantly elevated levels of inflammatory cytokines, including TNF-alpha and IL-6 [5]. Subsequent work has shown that anti-inflammatory interventions can improve depressive symptoms [6], and that administering pro-inflammatory cytokines to otherwise healthy individuals can induce depressive behavior [7].
This isn’t a niche finding. Estimates suggest that 30–50% of people with depression have measurably elevated inflammation. For these individuals, an SSRI alone is unlikely to resolve the problem because the medication doesn’t address the inflammatory cascade that’s disrupting neurotransmitter signaling, damaging neurons, and impairing neuroplasticity.
The clinical question becomes: What’s driving the inflammation? Common culprits include intestinal permeability (“leaky gut”), food sensitivities creating chronic immune activation, chronic infections, environmental toxin exposure, HPA axis dysfunction, and insulin resistance. Each of these can be assessed with appropriate testing.
The Gut-Brain Axis: Where Mental Health Begins
Your gut isn’t just digesting food—it’s actively shaping your brain chemistry. Approximately 90% of the body’s serotonin is produced in the gut, regulated by indigenous bacteria [8]. Gut microbes also produce GABA, dopamine precursors, and short-chain fatty acids that directly influence brain function. The vagus nerve provides a bidirectional communication highway between the gut and the brain, and approximately 70% of the immune system resides in the gut-associated lymphoid tissue.
When the gut microbiome is disrupted—through antibiotic use, chronic stress, poor diet, or infection—the downstream effects on mental health can be profound. Dysbiosis drives inflammation, compromises the gut barrier, reduces neurotransmitter precursor production, and shifts immune function toward a pro-inflammatory state. Comprehensive stool testing can reveal the specific patterns at play: whether someone has pathogenic overgrowth, insufficient beneficial flora, impaired digestive enzyme output, elevated gut inflammation markers like calprotectin, or compromised short-chain fatty acid production.
Nutrient Deficiencies: Missing the Building Blocks
Here’s a concept that seems obvious once you hear it but is routinely overlooked in conventional psychiatry: your brain cannot manufacture neurotransmitters without the raw materials. Serotonin synthesis requires tryptophan (from dietary protein), vitamin B6, magnesium, iron, and zinc. Dopamine synthesis requires tyrosine, iron, B6, and folate. If any of these are deficient, neurotransmitter production falters—regardless of what medication you’re taking.
Classic tryptophan depletion studies demonstrate this clearly. When researchers remove tryptophan from the diet of patients who have remitted from depression on SSRIs, 50–60% relapse back into depression within days. Restore the tryptophan, and they improve again [9]. The medication can only work with the serotonin that’s available—it can’t create serotonin from nothing.
Zinc deserves special attention. Meta-analytic evidence shows that low zinc levels are a significant risk factor for depression [10]. Zinc is concentrated in the brain’s frontal cortex, amygdala, and hippocampus—regions central to mood regulation. It modulates the serotonin receptor’s three-dimensional conformation, meaning that without adequate zinc, serotonin signaling becomes inefficient even when serotonin levels are normal. Zinc also influences the balance between glutamate and GABA and supports the conversion of pro-BDNF to mature BDNF, a molecule critical for neuroplasticity and neuronal survival.
Comprehensive nutritional testing goes far beyond a standard metabolic panel. It assesses organic acid markers of B vitamin function, amino acid status, mineral levels, fatty acid balance, and oxidative stress markers—revealing the specific nutrient deficiencies driving an individual’s symptom picture.
The HPA Axis: When Stress Biology Goes Wrong
The hypothalamic-pituitary-adrenal (HPA) axis is the body’s central stress response system, and its dysfunction is one of the most well-documented biological findings in depression. Studies estimate that 60–80% of people with depression have measurable HPA axis abnormalities [11].
Here’s where it gets clinically important: there are at least two distinct HPA patterns in depression, and they respond differently to treatment. Melancholic depression tends to present with elevated cortisol—these patients report insomnia, anxiety, dread, and appetite loss. Atypical depression is more commonly associated with low cortisol—these patients experience hypersomnia, fatigue, increased appetite, and a heavy, leaden quality in their limbs.
This distinction matters enormously for treatment selection. SSRIs lower cortisol. If someone has the high-cortisol pattern, an SSRI may genuinely help. But if someone has the low-cortisol pattern—which is common in treatment-resistant cases—an SSRI that further suppresses an already depleted cortisol response is unlikely to produce improvement. This is one of the reasons so many patients cycle through medications without finding relief: the medication mechanism doesn’t match their underlying biology.
Detailed cortisol testing—such as a multi-point salivary cortisol assessment with the cortisol awakening response—can differentiate these patterns and guide treatment decisions in a way that a standard serum cortisol draw simply cannot.
Thyroid Dysfunction: The Missed Connection
The relationship between thyroid function and depression is well established—thyroid disorders increase depression risk three- to fourfold [12]. What’s less appreciated is how often subclinical thyroid dysfunction contributes to depressive symptoms while flying under the radar of standard screening.
A standard TSH-only screen misses a remarkable amount of clinically relevant information. It doesn’t tell you about T4-to-T3 conversion (which is impaired by chronic stress), reverse T3 levels (which rise under stress and block thyroid receptor activity), or thyroid antibodies (which indicate autoimmune thyroiditis, present in up to 10% of the general population). IFM teaching emphasizes that optimal TSH for brain function is likely around 1.0–1.5 mIU/L—well below the upper end of most lab reference ranges.
Genetic variants in the DIO2 gene, which controls local T3 production in the brain, can mean that someone’s serum thyroid levels look adequate while their brain is functionally hypothyroid. This is one of the reasons genetic testing adds a meaningful dimension to functional medicine assessment.
Mitochondrial Dysfunction: The Energy Crisis
Your brain consumes roughly 20% of your body’s total energy despite being only 2% of your body weight. When mitochondria—the organelles responsible for cellular energy production—aren’t functioning properly, the brain is among the first organs to suffer. The result is the cluster of symptoms that many patients describe as the most debilitating aspects of their depression: profound fatigue, brain fog, poor concentration, and difficulty engaging in activities that used to feel effortless.
Mitochondrial dysfunction can stem from B vitamin deficiencies (particularly B1, B2, and B3, which are essential cofactors in the electron transport chain), CoQ10 depletion, magnesium insufficiency, oxidative stress from toxins or chronic inflammation, and genetic variants affecting energy production pathways. Organic acid testing can reveal markers of impaired mitochondrial function—such as elevated citric acid cycle intermediates or increased markers of oxidative stress—that would never appear on a standard blood panel.
Genetic Variants: Your Biochemical Individuality
Genes don’t cause depression, but they create vulnerabilities. Certain genetic variants—including those affecting methylation (MTHFR, COMT, MTR, MTRR), neurotransmitter metabolism (MAO-A, COMT), detoxification capacity (GST, CYP enzymes), and vitamin D utilization (VDR)—influence how efficiently your body performs the biochemical processes that support brain health.
MTHFR variants are perhaps the most clinically relevant example. Present in 30–40% of the population, these variants impair the body’s ability to convert folic acid into methylfolate—the active form required for neurotransmitter synthesis, DNA methylation, and homocysteine metabolism [13]. People with these variants may need significantly higher doses of folate in a specific methylated form to maintain adequate brain function.
Genetic testing doesn’t provide diagnoses—it provides a personalization map. When you know that someone has variants affecting both methylation and detoxification, you can anticipate their nutritional needs, understand why they might be more sensitive to environmental toxins, and design interventions that work with their unique biochemistry rather than against it.
Environmental Toxins: The Invisible Burden
Heavy metals, pesticides, mycotoxins, and industrial chemicals are ubiquitous in modern environments. These toxins damage mitochondria, disrupt hormone signaling, impair detoxification pathways, trigger neuroinflammation, and can cause direct neurotoxicity. Many cases of treatment-resistant depression improve substantially once toxic burden is identified and addressed through enhanced detoxification support and exposure reduction.
Why Comprehensive Testing Changes the Game
Here’s the fundamental problem with conventional psychiatric treatment: without objective biological data, clinicians are guessing. They’re matching symptom clusters to medication categories and hoping for a good response. When the first medication doesn’t work, they try another—and another—through the same trial-and-error process that STAR*D documented so thoroughly.
Functional medicine for depression replaces guessing with data. When you simultaneously assess gut function, nutritional status, hormone patterns, genetic variants, inflammatory markers, and metabolic health, patterns emerge that are invisible on any single test. You might discover that someone’s depression is being driven by a combination of intestinal permeability, zinc and B6 deficiency, a flattened cortisol curve, elevated inflammatory markers, and an MTHFR variant impairing methylation—all interacting with each other in ways that no single medication could address.
This kind of comprehensive assessment requires the right panel of tests. Blood work reveals thyroid function, inflammatory markers, metabolic health, nutrient levels, and anemia patterns. Urine testing captures cortisol rhythm throughout the day, sex hormone metabolites, organic acid markers of nutrient function and mitochondrial health, and neurotransmitter metabolite patterns. Stool testing maps the microbiome, assesses digestive enzyme output, and measures gut inflammation and barrier function. Genetic testing identifies the variants that shape biochemical individuality. And food sensitivity testing identifies immune-mediated reactions to specific foods that may be silently driving inflammation.
No single test tells the full story. But together, they reveal the interconnected biological landscape underlying someone’s depression—and they make it possible to design targeted interventions that address root causes rather than merely suppressing symptoms.
What Treatment Looks Like When You Have the Data
With comprehensive testing in hand, treatment becomes targeted and phased rather than one-size-fits-all.
A typical protocol unfolds over roughly four months in three phases. Phase 1 focuses on foundations: addressing gut dysfunction, repleting critical nutrient deficiencies, reducing inflammation, and stabilizing blood sugar. This is where you start because gut health and nutritional status influence everything downstream—hormone production, neurotransmitter synthesis, detoxification capacity, and immune regulation.
Phase 2 shifts toward optimization: fine-tuning HPA axis support based on cortisol patterns, addressing thyroid function, supporting methylation based on genetic data, and beginning more targeted neurotransmitter precursor work. By this point, the foundational work has created the biological conditions for these interventions to be effective.
Phase 3 focuses on resilience and maintenance: consolidating gains, transitioning to sustainable supplement protocols, reinforcing dietary and lifestyle practices, and establishing monitoring plans.
Throughout all phases, functional medicine for depression works alongside—not against—existing treatments. Patients don’t need to stop their medications to begin this work. In fact, many find that as root causes are addressed, their medications begin to work better because the biological environment supporting brain function has improved. Over time, some patients work with their prescribers to reduce or discontinue medications, but this is always done carefully and collaboratively.
The Integration Imperative
Depression is a biopsychosocial condition. Addressing biological root causes through functional medicine doesn’t replace psychotherapy, social connection, movement, stress management, or spiritual practice—it creates the biological foundation that makes these interventions more effective. A brain that has adequate nutrients, balanced inflammation, functional mitochondria, and a healthy stress response is a brain that can engage more fully in the psychological and social work of recovery.
The IFM framework explicitly incorporates modifiable lifestyle factors—sleep, exercise, nutrition, stress, and relationships—as central components of treatment, not afterthoughts. This integration of biological intervention with lifestyle medicine and psychological support represents a more complete model of care for depression than any single approach can offer alone.
A Different Path Forward
If you’ve tried multiple medications without lasting improvement, or if you suspect that something biological is being missed in your treatment, functional medicine for depression may reveal answers that standard psychiatric evaluation cannot provide. The research is clear that depression involves far more than a neurotransmitter imbalance, and the tools now exist to assess the broader biological landscape—gut function, nutritional status, hormone patterns, genetic variants, inflammatory markers, and metabolic health—with precision that was unavailable even a decade ago.
The question isn’t whether biology matters in depression. The question is whether you’ve looked at enough of it.
About the Author:
Dr. David Wiss, PhD, RDN, FMCP, is a functional medicine practitioner specializing in treatment-resistant mental health conditions. His work integrates nutritional psychiatry, gut-brain medicine, and advanced functional testing to help patients address the root causes of depression, anxiety, and other psychiatric conditions.
References
[1] Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006;163(11):1905-1917.
[2] Pigott HE, Kim T, Xu C, Kirsch I, Amsterdam J. What are the treatment remission, response and extent of improvement rates after up to four trials of antidepressant therapies in real-world depressed patients? A reanalysis of the STAR*D study’s patient-level data with fidelity to the original research protocol. BMJ Open. 2023;13(7):e063095.
[3] Moncrieff J, Cooper RE, Stockmann T, Amendola S, Hengartner MP, Horowitz MA. The serotonin theory of depression: a systematic umbrella review of the evidence. Mol Psychiatry. 2022;28(8):3243-3256.
[4] Jauhar S, Arnone D, Baldwin DS, et al. A leaky umbrella has little value: evidence clearly indicates the serotonin system is implicated in depression. Mol Psychiatry. 2023;28(8):3149-3152.
[5] Dowlati Y, Herrmann N, Swardfager W, et al. A meta-analysis of cytokines in major depression. Biol Psychiatry. 2010;67(5):446-457.
[6] Köhler O, Benros ME, Nordentoft M, et al. Effect of anti-inflammatory treatment on depression, depressive symptoms, and adverse effects: a systematic review and meta-analysis of randomized clinical trials. JAMA Psychiatry. 2014;71(12):1381-1391.
[7] Dantzer R, O’Connor JC, Freund GG, Johnson RW, Kelley KW. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci. 2008;9(1):46-56.
[8] Yano JM, Yu K, Donaldson GP, et al. Indigenous bacteria from the gut microbiota regulate host serotonin biosynthesis. Cell. 2015;161(2):264-276.
[9] Delgado PL, Charney DS, Price LH, Aghajanian GK, Landis H, Heninger GR. Serotonin function and the mechanism of antidepressant action: reversal of antidepressant-induced remission by rapid depletion of plasma tryptophan. Arch Gen Psychiatry. 1990;47(5):411-418.
[10] Swardfager W, Herrmann N, Mazereeuw G, Goldberger K, Harimoto T, Lanctôt KL. Zinc in depression: a meta-analysis. Biol Psychiatry. 2013;74(12):872-878.
[11] Pariante CM, Lightman SL. The HPA axis in major depression: classical theories and new developments. Trends Neurosci. 2008;31(9):464-468.
[12] Fountoulakis KN, Iacovides A, Grammaticos P, et al. Thyroid function in clinical subtypes of major depression: an exploratory study. BMC Psychiatry. 2004;4:6.
[13] Gilbody S, Lewis S, Lightfoot T. Methylenetetrahydrofolate reductase (MTHFR) genetic polymorphisms and psychiatric disorders: a HuGE review. Am J Epidemiol. 2007;165(1):1-13.
